PW PeptideWars Evidence league

Growth hormone secretagogues

Ipamorelin

A selective growth hormone secretagogue studied in early human pharmacology and gastrointestinal motility contexts.

Growth hormone secretagogueGhrelin mimeticNNC 26-0161

Concise answer

What is Ipamorelin?

Ipamorelin is a growth hormone secretagogue with limited human pharmacology data. It is not FDA-approved for anti-aging, fat loss, recovery, or bodybuilding claims.

Definition

What It Is

Ipamorelin is a synthetic peptide that acts through growth hormone secretagogue pathways, often discussed as a ghrelin-mimetic compound.

Status

Legal and Regulatory Notes

  • FDA: Not FDA-approved as a marketed medication.
  • Research: Human studies characterize pharmacokinetics and GH response, but do not validate broad wellness claims.
  • Sport: Growth hormone secretagogues are high-risk under anti-doping rules.

Research map

How Ipamorelin Is Being Studied

Growth hormone pharmacokinetics and pharmacodynamicsGastrointestinal motility researchSelectivity compared with older growth hormone releasing peptidesAnti-doping and unapproved peptide use

People

Human Research

Human volunteer studies show GH-response characterization. Those data do not prove benefits for recovery, body composition, sleep, or longevity.

Models

Animal and Cell Research

Animal models have explored gastrointestinal motility and other mechanisms, but translation to consumer peptide claims is uncertain.

Safety

Known Risks and Side Effects

  • Unknown long-term safety outside research
  • Potential hormone-axis adverse effects
  • Anti-doping risk
  • Unregulated product quality and misleading stack claims

Compliance

Interpretation Guardrails

  • No route, dose, cycle, or stack guidance is provided.
  • Growth hormone symptoms, deficiency, or endocrine disease require licensed medical care.
  • Research-only product labeling is not a substitute for FDA approval.

Internal links

Related Battles and Profiles

Battle Sermorelin vs Ipamorelin A GHRH analog with older clinical literature versus a selective GH secretagogue with limited human pharmacology data. Battle CJC-1295 vs Ipamorelin Two GH-axis research peptides compared by mechanism, evidence, risk, and anti-doping status. Profile CJC-1295 An investigational long-acting GHRH analog studied for growth hormone and IGF-1 signaling. Profile Sermorelin A GHRH analog historically studied for growth hormone deficiency testing and pediatric growth contexts. Profile Tesamorelin An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication. Guide Growth Hormone Secretagogues CJC-1295, ipamorelin, sermorelin, and tesamorelin compared by mechanism, evidence, and regulatory status. Guide Research-Only Peptides How to spot compounds where marketing has outrun human evidence and regulatory approval.
FAQ

Common Questions

Is ipamorelin FDA-approved?

No. Ipamorelin is not an FDA-approved marketed medication.

Is ipamorelin safer than CJC-1295?

There is not enough clinical outcome evidence to declare a broad safety winner. Mechanisms differ, but both require caution.

Can PeptideWars compare ipamorelin stacks?

PeptideWars can compare evidence and mechanisms, but it does not provide stacking, cycling, dosing, or sourcing guidance.

Sources

Citations and Official References

  1. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers PubMed
  2. Ipamorelin, the First Selective Growth Hormone Secretagogue PubMed
  3. The Prohibited List WADA

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.